Hikma Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 3/6

De winst van Hikma Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -18.8%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 12.9%. De inkomsten zijn groeide met een gemiddeld percentage van 6.3% per jaar. Het rendement op het eigen vermogen Hikma Pharmaceuticals bedraagt 12.6% en de nettomarge bedraagt 9.4%.

Belangrijke informatie

-18.8%

Groei van de winst

-16.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	7.3%
Inkomstengroei	6.3%
Rendement op eigen vermogen	12.6%
Nettomarge	9.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Hikma Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:H5P Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	3,017	285	651	146
31 Mar 24	2,946	238	642	148
31 Dec 23	2,875	190	632	149
30 Sep 23	2,803	168	619	144
30 Jun 23	2,731	146	606	139
31 Mar 23	2,624	167	604	142
31 Dec 22	2,517	188	601	144
30 Sep 22	2,534	267	593	149
30 Jun 22	2,550	346	585	153
31 Mar 22	2,552	384	573	148
31 Dec 21	2,553	421	561	143
30 Sep 21	2,489	444	535	139
30 Jun 21	2,425	467	509	134
31 Mar 21	2,383	449	508	136
31 Dec 20	2,341	431	506	137
30 Sep 20	2,317	472	503	134
30 Jun 20	2,292	513	500	130
31 Mar 20	2,250	500	494	128
31 Dec 19	2,207	486	487	126
30 Sep 19	2,173	424	481	128
30 Jun 19	2,138	361	475	129
31 Mar 19	2,104	322	471	124
31 Dec 18	2,070	282	467	118
30 Sep 18	2,045	-262	464	110
30 Jun 18	2,020	-806	460	102
31 Mar 18	1,978	-824	467	109
31 Dec 17	1,936	-843	474	115
30 Sep 17	1,950	-338	462	122
30 Jun 17	1,963	166	450	129
31 Mar 17	1,957	161	440	128
31 Dec 16	1,950	155	429	126
30 Sep 16	1,782	166	411	100
30 Jun 16	1,613	176	392	73
31 Mar 16	1,527	214	372	55
31 Dec 15	1,440	252	352	36
30 Sep 15	1,450	248	346	46
30 Jun 15	1,460	243	339	56
31 Mar 15	1,475	261	342	56
31 Dec 14	1,489	278	345	55
30 Sep 14	1,477	293	339	46
30 Jun 14	1,465	308	333	37
31 Mar 14	1,415	260	322	34
31 Dec 13	1,365	212	311	31

Kwaliteitswinsten: H5P heeft een grote eenmalige verlies van $264.0M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (9.4%) H5P } zijn hoger dan vorig jaar (5.3%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van H5P is de afgelopen 5 jaar met 18.8% per jaar gedaald.

Versnelling van de groei: De winstgroei van H5P over het afgelopen jaar ( 95.2% ) overtreft het 5-jarig gemiddelde ( -18.8% per jaar).

Winst versus industrie: De winstgroei H5P over het afgelopen jaar ( 95.2% ) overtrof de Pharmaceuticals -sector 28.7%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 12.6% ) van H5P wordt als laag beschouwd.

Hikma Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: US$1.02 (vs US$0.59 in 1H 2023)

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Insider recently sold €1.0m worth of stock

First half dividend of US$0.32 announced

First half 2024 earnings released: EPS: US$1.02 (vs US$0.59 in 1H 2023)

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 22% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 20% undervalued

New minor risk - Insider selling

Insider recently sold €631k worth of stock

Now 20% undervalued

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

New minor risk - Dividend sustainability

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Now 21% undervalued

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 20% undervalued

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Now 20% undervalued

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Now 21% undervalued

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: €25.80

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €26.40

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.

Hikma Pharmaceuticals PLC Provides Update on Generic Advair Diskus®

Hikma Pharmaceuticals PLC Launches Generic Advair Diskus®